- Home
- ASPN vs AKRO Comparison
ASPN vs AKRO Comparison
Compare ASPN & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASPN
- AKRO
- Stock Information
- Founded
- ASPN 2001
- AKRO 2017
- Country
- ASPN United States
- AKRO United States
- Employees
- ASPN N/A
- AKRO N/A
- Industry
- ASPN RETAIL: Building Materials
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ASPN Consumer Discretionary
- AKRO Health Care
- Exchange
- ASPN Nasdaq
- AKRO Nasdaq
- Market Cap
- ASPN 1.5B
- AKRO 2.1B
- IPO Year
- ASPN 2014
- AKRO 2019
- Fundamental
- Price
- ASPN $18.18
- AKRO $31.59
- Analyst Decision
- ASPN Strong Buy
- AKRO Strong Buy
- Analyst Count
- ASPN 9
- AKRO 7
- Target Price
- ASPN $32.00
- AKRO $43.20
- AVG Volume (30 Days)
- ASPN 3.0M
- AKRO 441.5K
- Earning Date
- ASPN 11-06-2024
- AKRO 11-11-2024
- Dividend Yield
- ASPN N/A
- AKRO N/A
- EPS Growth
- ASPN N/A
- AKRO N/A
- EPS
- ASPN 0.02
- AKRO N/A
- Revenue
- ASPN $357,245,000.00
- AKRO N/A
- Revenue This Year
- ASPN $72.06
- AKRO N/A
- Revenue Next Year
- ASPN $30.15
- AKRO N/A
- P/E Ratio
- ASPN $954.90
- AKRO N/A
- Revenue Growth
- ASPN 87.96
- AKRO N/A
- 52 Week Low
- ASPN $7.37
- AKRO $11.36
- 52 Week High
- ASPN $33.15
- AKRO $37.00
- Technical
- Relative Strength Index (RSI)
- ASPN 32.60
- AKRO 66.34
- Support Level
- ASPN $18.95
- AKRO $29.34
- Resistance Level
- ASPN $20.19
- AKRO $32.15
- Average True Range (ATR)
- ASPN 1.47
- AKRO 1.26
- MACD
- ASPN -0.39
- AKRO 0.10
- Stochastic Oscillator
- ASPN 3.31
- AKRO 99.74
About ASPN Aspen Aerogels Inc.
Aspen Aerogels Inc is an aerogel technology company that designs, develops, and manufactures high-performance aerogel insulation used in the energy industrial and sustainable insulation markets. The company also conducts research and development related to aerogel technology supported by funding from several agencies of the United States of America government and other institutions in the form of research and development contracts. It is engaged in two operating segment Energy Industrial and Thermal Barrier. Geographically, it operates in the U.S. and also has a presence in other International countries. It generates the majority of its revenue from the Energy Industrial segment and the United States market. Some of its products include Pyrogel XTE; Cryogel Z; Spaceloft Subsea; and others.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.